

New Orleans, Louisiana – 2000 (N=274)

Figure A. Age of GISP participants, in years, 2000




Figure C. Percentage of GISP participants identifying as men who have sex with men, 1988–2000




Figure B. Race/ethnicity of GISP participants, 2000






Figure D. Reason for visit among GISP participants, 2000



New Orleans, Louisiana – 2000 (N=274)

Figure E. Previous episode of gonorrhea among GISP participants, 1991–2000




*Data first collected in 1991.

**Data first collected in 1992.

Note: Data points not shown when >30% data missing.

Figure F. Drugs used to treat gonorrhea among GISP participants, 2000



Drug	Percentage
Ciprofloxacin	0.38%
Cefixime	1.52%
None	95.06%
Spectinomycin	0.76%
Ceftriaxone 250	0.38%
Other	0.38%

Figure G. Drugs used to treat *Chlamydia trachomatis* infection among GISP participants, 2000





Figure H. Resistance to penicillin and tetracycline among GISP isolates, 2000



Resistance Category	Percentage
Pen & Tet Suscep	63.14%
PPNG	11.31%
PenR	8.39%
TetR	5.47%
TRNG	5.84%
CMRNG	5.84%

New Orleans, Louisiana – 2000 (N=274)

Figure I. Decreased susceptibility to ceftriaxone among GISP isolates, 1988–2000

No isolates with decreased susceptibility to ceftriaxone have been identified at this clinic.

Figure J. Decreased susceptibility to cefixime among GISP isolates, 1992–2000





Figure K. Intermediate resistance and resistance to ciprofloxacin among GISP isolates, 1990–2000



Note: Susceptibility to ciprofloxacin first measured in 1990.

Figure L. Decreased susceptibility to azithromycin among GISP isolates, 1992–2000

No isolates with decreased susceptibility to azithromycin have been identified at this clinic.